Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Investment analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for Xencor in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will post earnings per share of ($0.77) for the quarter, down from their prior estimate of ($0.66). The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor's Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.88) EPS and FY2026 earnings at ($3.24) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. During the same period last year, the business earned ($1.11) EPS. The business's revenue was up 104.6% on a year-over-year basis.

XNCR has been the subject of several other research reports. Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. Wells Fargo & Company reduced their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. William Blair began coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Barclays reduced their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.50.

Xencor Stock Performance

Shares of XNCR stock opened at $8.33 on Monday. The company has a market capitalization of $592.70 million, a price-to-earnings ratio of -2.60 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a 50-day simple moving average of $10.73 and a 200 day simple moving average of $17.61. Xencor has a 52 week low of $7.16 and a 52 week high of $27.24.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC raised its position in shares of Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after buying an additional 78,066 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Xencor by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 130,354 shares of the biopharmaceutical company's stock valued at $2,621,000 after buying an additional 3,635 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV raised its position in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 813 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Xencor by 24.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,839 shares of the biopharmaceutical company's stock valued at $341,000 after buying an additional 2,946 shares in the last quarter.

Insiders Place Their Bets

In other Xencor news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.76% of the company's stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.